Business Information
The group's principal activity is to develop, manufacture and market oxygen therapeutics. The products include hemopure and oxyglobin. Hemopure is an alternative to red blood cell transfusions as well as for use in the treatment of other critical care conditions. Oxyglobin is similar to hemopure except for its molecular distribution and has the same advantage over red blood cells. Oxyglobin is used in the treatment of canine anemia, mainly for veterinary purposes. Biopure (R), hemopure(R) and oxyglobin(R) are the registered trademarks of the group. The group's products are marketed through advertising, direct mail, educational seminars, conference calls, lectures at congresses and attendance at trade shows. The group has 24 patents and 11 applications pending relating to our oxygen therapeutics.
|
|
Name |
Title
|
Email
|
| David Judelson | Vice Chmn. | N/A | | Martin Leon | Chmn. - Scientific Advisory Board | N/A | | Zafiris Zafirelis | Chmn., CEO, Pres. | N/A | | Francis Murphy | CFO | N/A | | Barry Scott | VP - Business Development | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,715 | (26,454) | | 2005 | 2,110 | (28,671) | | 2004 | 3,750 | (41,665)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
